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Background: Despite maximal therapy, patients with advanced heart failure frequently experience continuous deterioration, while end organ 
dysfunction precludes long term mechanical support (LVAD) or transplantation. We examined the role of long term IABP support in unstable patients 
with idiopathic dilated cardiomyopathy (IDC).
Methods: In 9, NYHA class IV patients with IDC, 48.8±13.1 years old, with progressively worsening symptoms despite optimum medical therapy, 
end organ failure and not candidates for surgical therapy, IABP was implanted. Four patients were in INTERMACS category 1 (systolic pressure 68±17 
mm Hg) and 5 in INTERMACS category 2 (systolic pressure 94±6 mm Hg). Echocardiographic, biochemical, hemodynamic indices and tolerance to 
medical therapy were assessed.
Results: Duration of IABP support was 71±40 days. INTERMACS 1 pts were not stabilized and died within one month, under support. All INTERMACS 
2 pts showed substantial improvement: right atrial pressure (from 16±7 to 3±1.5 mmHg p=0.01), pulmonary capillary wedge pressure (from 
27±4 to 9.80±6.0 mmHg p=0.005), cardiac index (from 1.2±0.2 to 1.8±0.5 l/min/m2, p=0.04), mean pulmonary artery pressure (from 34±9 to 
24±10 mmHg, p=0.001), BNP (from 2526±1303 to 382±245 pg/ml, p=0.03), bilirubin (from 3.0±0.0.8 to 1.0±0.5 mg/dl, p=0.001). They also 
tolerated higher doses of b- blockers (from 12.50±21.65 to 42.50±28.9 mg, p=0.04). Four underwent successful cardiac surgery (one mitral valve 
replacement that stabilized him in NYHA class II for 18 months, two LVAD implantation as destination therapy and one BiVAD implantation as bridge 
to transplantation). One experienced recovery and remains at NYHA class I for 9 months (despite an 8 year history of IDC). Vascular complications 
and thromboembolic events were not observed although ischemia of the leg occurred in four INTERMACS 1 patients.
Conclusions: IABP is a relatively safe device for medium to long term support of patients with advanced stage heart failure, without other 
treatment options. Long term IABP support improves significantly left and right heart as well as end organ function, rendering patients eligible for 
heart transplantation or permanent mechanical support.
